# SUMMARY OF SAFETY AND EFFECTIVENESS

February 16, 2010.

Trade Name: BaseSens I Blood Glucose Monitoring System

Common Name: Blood Glucose Monitoring System

Classification Name: System, Test, Blood Glucose, Over the Counter

Classification Panel: Clinical Chemistry

Applicant:

Eran Bashan, Ph.D. President

Hygieia, Inc.   
330 E. Liberty Street Ann Arbor, MI 48104 USA   
Tel: 734-527-9160   
Cell: 734-316-2227 Fax: 734-623-8289

All questions and/or comments concerning this document should be made to:

Robert J. Bard, Esq. Managing Director

HealthCare Technologies Consultants   
PO Box 506   
South Lyon, MI 48178   
USA   
Tel: 248-573-5040   
Cell: 734-330-5990

# 1.0 DESCRIPTION OF THE PRODUCT

The BaseSens 1 Blood Glucose Monitoring System is identical to the i-Sens CareSens N Blood Glucose Monitoring System. The Hygieia BaseSens I Blood Glucose Monitoring System is a rebranded CareSens N System. Rebranding here is intended to be understood as all components of the CareSens N System have been relabeled with the Hygieia name BaseSens I or BaseSens I Blood Glucose Monitoring System.

As fully identical to the i-Sens CareSens N Blood Glucose Monitoring System, the BaseSens I Blood Glucose Monitoring System is thereby substantially equivalent to the i-Sens CareSens N Blood Glucose Monitoring System.

1.1 The Hygieia, Inc. BaseSens I Blood Glucose Monitoring System

1.1.1 The System includes the BaseSens I blood glucose meter, test strips and controls.

<table><tr><td rowspan=1 colspan=1>Classification or descriptor</td><td rowspan=1 colspan=1>Name or designation</td></tr><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>BaseSens I Blood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Common Name</td><td rowspan=1 colspan=1>Blood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>System, Test, Blood Glucose, Over theCounter</td></tr><tr><td rowspan=1 colspan=1>Classification Panel</td><td rowspan=1 colspan=1>Chemistry</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>NBW (also CGA and JJX)</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>862.1345</td></tr></table>

# 2.0 PREDICATE DEVICES

2.1 i-Sens CareSens Blood Glucose Monitoring System K080923 and the CareSens N Blood Glucose Monitoring System (k083468) are manufactured by i-SENS, Seoul, South Korea.

2.1.1 The device under review is also manufactured by i-SENS, Seoul, South Korea. The BaseSens I Blood Glucose Monitoring System is a re-branding of the CareSens N System and is substantial equivalent to the CareSens N System.

# 3.0 INDICATIONS FOR USE

3.1 The BaseSens I Blood Glucose Monitoring System and the CareSens N System have the following indications for use.

<table><tr><td>BaseSens I Blood Glucose Monitoring System</td><td>CareSens N Blood Glucose Monitoring System</td></tr><tr><td>The BaseSens I Blood Glucose Monitoring System is used for the quantitative measurement of glucose levels in capillary whole blood as an aid in monitoring the effectiveness of diabetes management at home or in clinical settings. The BaseSens I Blood Glucose Monitoring System should be used only for testing outside the body</td><td>Same</td></tr><tr><td colspan="1" rowspan="1">(in vitro diagnostic use only). The BaseSens IBlood Glucose Monitoring System is not intendedfor the diagnosis of or screening for diabetesmellitus, and is not intended for use on neonates.Testing sites include the fingertip along withalternate sites testing (AsT) on the forearm, palm,thigh and calf. AST in this system can be usedonly during steady-state blood glucose conditions</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">BaseSens I Test Strip is used with the BaseSens IBlood Glucose Meter for quantitatively measuringglucose in capillary whole blood. The BaseSens ITest Strip is intended for self-testing outside thebody (in vitro diagnostic use only). The BaseSensI Test Strips are not intended for the diagnosis ofor screening for diabetes mellitus, and are notintended for use on neonates. Testing sitesinclude the fingertip along with alternate sitestesting (AST) on the forearm, palm, thigh andcalf. AST in this system can be used only duringsteady-state blood glucose conditions.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">BaseSens I Control A&amp;B Solutions are red liquidto check that both the meters and test strips areworking together properly. It contains a knownrange of glucose as written on the bottle.</td><td colspan="1" rowspan="1">Same.</td></tr></table>

# 4.0 DEVICE DESCRIPTIONS

4.1 Specifications

4.1.1

The BaseSens I Blood Glucose Monitoring System and the CareSens N Blood Glucose Monitoring System including the following identical system components.

4.1.1.1 BaseSens I Meter (included in the System package)   
4.1.1.2 BaseSens I Test strips (included in the System package)   
4.1.1.3 BaseSens I Control Solutions. The Control Solutions are not included in the System package. This component can be purchased separately.

4.1.2 The BaseSens I Blood Glucose Monitoring System and the CareSens N Blood Glucose Monitoring System have identical product specifications.

# 4.2 Materials

The components used in the manufacture of the BaseSens I meter are identical to those of the i-Sens CareSens N meter.

4.2.2 The components used in the manufacture of the BaseSens I test strips are identical to those of the i-Sens CareSens N test strips.

# 4.2.3

The components used in the manufacture of the BaseSens I control solution are identical to those of the i-Sens CareSens N control solution.

5.0 COMPARISON OF BASESENS SYSTEM AND ITS PREDICATES   

<table><tr><td colspan="4" rowspan="1">Device Features</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">BaseSens I BGMS</td><td colspan="1" rowspan="1">CareSens N BGMS</td><td colspan="1" rowspan="1">CareSens BGMS</td></tr><tr><td colspan="1" rowspan="1">Enzyme</td><td colspan="1" rowspan="1">Glucose Oxidase</td><td colspan="1" rowspan="1">Glucose Oxidase</td><td colspan="1" rowspan="1">Glucose Oxidase</td></tr><tr><td colspan="1" rowspan="1">MeasurementPrinciple</td><td colspan="1" rowspan="1">Amperometric method</td><td colspan="1" rowspan="1">Amperometric method</td><td colspan="1" rowspan="1">Amperometric method</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">Glucose oxidasechemical reaction.The instrumentmeasures the extentof current cause bypresence of glucosein sample.</td><td colspan="1" rowspan="1">Glucose oxidasechemical reaction.The instrumentmeasures the extentof current cause bypresence of glucosein sample.</td><td colspan="1" rowspan="1">Glucose oxidasechemical reaction. Theinstrument measures theextent of current causeby presence of glucosein sample.</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The test strips workwith the device toquantitativelymeasure glucose incapillary whole blood.The test Strips are forin vitro (i.e., outsidethe body) diagnosticuse only.</td><td colspan="1" rowspan="1">The test strips workwith the device toquantitativelymeasure glucose incapillary whole blood.The test Strips are forin vitro (i.e., outsidethe body) diagnosticuse only.</td><td colspan="1" rowspan="1">The test strips work withthe device toquantitatively measureglucose in capillarywhole blood. The testStrips are for in vitro (i.,outside the body)diagnostic use only.</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Fresh capillary wholeblood</td><td colspan="1" rowspan="1">Fresh capillary wholeblood</td><td colspan="1" rowspan="1">Fresh capillary wholeblood</td></tr><tr><td colspan="1" rowspan="1">Electrode</td><td colspan="1" rowspan="1">Carbon</td><td colspan="1" rowspan="1">Carbon</td><td colspan="1" rowspan="1">Carbon</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Plasma-equivalent</td><td colspan="1" rowspan="1">Plasma-equivalent</td><td colspan="1" rowspan="1">Plasma-equivalent</td></tr><tr><td colspan="1" rowspan="1">Test Time (seconds)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Sample volume (Î¼L)</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">0.5</td></tr><tr><td colspan="1" rowspan="1">Memory</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Test Range(mg/dL)</td><td colspan="1" rowspan="1">20~600</td><td colspan="1" rowspan="1">20~600</td><td colspan="1" rowspan="1">20~600</td></tr><tr><td colspan="1" rowspan="1">Hematocrit range(%)</td><td colspan="1" rowspan="1">20~60 (below400mg/dL)</td><td colspan="1" rowspan="1">20~60 (below400mg/dL)</td><td colspan="1" rowspan="1">20~60 (below 400mg/dL)</td></tr><tr><td colspan="1" rowspan="1">Glucose units</td><td colspan="1" rowspan="1">Either mg/dL ormmol/L</td><td colspan="1" rowspan="1">Either mg/dL ormmol/L</td><td colspan="1" rowspan="1">Either mg/dL or mmol/L</td></tr><tr><td colspan="1" rowspan="1">Checking thesyste</td><td colspan="1" rowspan="1">Control solution</td><td colspan="1" rowspan="1">Control solution</td><td colspan="1" rowspan="1">Control solution</td></tr><tr><td colspan="1" rowspan="1">Alternate SiteCapability</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Operating Humidity</td><td colspan="1" rowspan="1">10~90%</td><td colspan="1" rowspan="1">10~90%</td><td colspan="1" rowspan="1">10~90%</td></tr><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">BaseSens I BGMS</td><td colspan="1" rowspan="1">CareSens N BGMS</td><td colspan="1" rowspan="1">CareSens BGMS</td></tr><tr><td colspan="1" rowspan="1">Coding</td><td colspan="1" rowspan="1">Automatic codeidentification</td><td colspan="1" rowspan="1">Automatic codeidentification</td><td colspan="1" rowspan="1">Manual input by button</td></tr><tr><td colspan="1" rowspan="1">Self-diagnosis ofcode identificationfunction</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Three time setAlarms and 2-hourpost-meal Alarm</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Post-meal flagging</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Number of buttons</td><td colspan="1" rowspan="1">3 buttons</td><td colspan="1" rowspan="1">3 buttons</td><td colspan="1" rowspan="1">2 buttons (CareSens I1)1 button (CareSensPOP)</td></tr></table>

Conclusion: The BaseSens I Blood Glucose Monitoring System does not raise any new safety and efficacy concerns when compared to the cleared CareSens N Blood Glucose Monitoring System.

The BaseSens I Blood Glucose Monitoring System is identical to the i-Sens CareSens N Blood Glucose Monitoring System. The Hygieia BaseSens I Blood Glucose Monitoring System is a rebranded CareSens N Blood Glucose Monitoring System. As fully identical to the i-Sens CareSens N Blood Glucose Monitoring System, the BaseSens I Blood Glucose Monitoring System is thereby substantially equivalent to the i-Sens CareSens N Blood Glucose Monitoring System.

Hygieia, Inc.   
c/o Healthcare Technologies Consultants Robert J. Bard, Esq.   
Managing Director   
P.O. Box 506   
South Lyon, MI 48178

Re: k093475 Trade/Device Name: BaseSens I Blood Glucose Monitoring System Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, CGA, JJX Dated: January 17, 2010 Received: January 19, 2010

Dear Robert J. Bard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/e21ab42a824eff50f74c4092790144af93f7307de3f16841978fb1bb3304bc7a.jpg)

Courtnty C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (k093475):

Device Name: BaseSens I Blood Glucose Monitoring System

Indication for Use: The BaseSens I Blood Glucose Monitoring System is used for the quantitative measurement of glucose levels in capillary whole blood as an aid in monitoring the effectiveness of diabetes management at home or in clinical settings. The BaseSens I Blood Glucose Monitoring System should be used only for testing outside the body (in vitro diagnostic use only). The BaseSens I Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. Testing sites include the fingertip along with alternate sites testing (AST) on the forearm, palm, thigh and calf. AST in this system can be used only during steady-state blood glucose conditions.

BaseSens I Test Strip is used with the BaseSens I Blood Glucose Meter for quantitatively measuring glucose in capillary whole blood. The BaseSens I Test Strip is intended for self-testing outside the body (in vitro diagnostic use only). The BaseSens I Test Strips are not intended for the diagnosis of or screening for diabetes mellitus, and are not intended for use on neonates. Testing sites include the fingertip along with alternate sites testing (AST) on the forearm, palm, thigh and calf. AST in this system can be used only during steady-state blood glucose conditions.

BaseSens I Control A&B Solutions are a red liquid to check that both the meters and test strips a worke o Its   n    et

Prescription Use _X and/or Over the Counter Use _x (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Cncc  CDRH, Offe f In Vi iagosi Devicevaluati nd Safey IVD

![](images/e8ce845d4834d83af25cd8810467c4d3e91e2342c607e86c7ee67cba0a3e6da4.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

.510(k) k093475